- NeuroScientific Biopharmaceuticals (NSB) recruits its first subject for an early-phase clinical trial
- The clinical stage drug development company announced the recruitment for its trial for lead drug candidate, EmtinB to treat neurodegenerative conditions, such as multiple sclerosis and Alzheimer’s disease
- The clinical trial is being undertaken by WA-based clinical research partner, Linear Clinical Research, and will see up to 30 healthy volunteers undergo treatment
- This will then be used to guide efficacy outcomes during future trials
- NeuroScientific Biopharmaceuticals is in the grey, trading at 17.5 cents at 12:36 pm AEST
NeuroScientific Biopharmaceuticals (NSB) has recruited its first subject for its early-phase clinical trial.
The clinical stage drug development company announced the recruitment for its trial for lead drug candidate, EmtinB.
The drug is hoped to be a first-in-class treatment with disease modifying potential for neurodegenerative conditions, such as multiple sclerosis and Alzheimer’s disease.
EmtinB has been modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body’s innate immune response to cell injury.
The clinical trial is being undertaken by WA-based clinical research partner, Linear Clinical Research, and will see up to 30 healthy volunteers undergo treatment.
The study will involve the assessment of biomarkers in human blood samples that indicate proof of the mechanism of activity of EmtinB in humans.
This can then be used to guide efficacy outcomes during future trials.
NeuroScientific’s Managing Director and Chief Executive Officer Matt Liddelow said the news marks another historic achievement for the company.
Matt Liddelow described the news as “a major milestone in developing EmtinB as a much-needed therapeutic treatment with disease modifying potential for patients with Multiple sclerosis and Alzheimer’s disease.”
NeuroScientific Biopharmaceuticals were in the grey, trading at 17.5 cents at 12:36 pm AEST.